ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.
Archer Goode, E
MetadataShow full item record
Using genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screens to understand endocrine drug resistance, we discovered ARID1A and other SWI/SNF complex components as the factors most critically required for response to two classes of estrogen receptor-alpha (ER) antagonists. In this context, SWI/SNF-specific gene deletion resulted in drug resistance. Unexpectedly, ARID1A was also the top candidate in regard to response to the bromodomain and extraterminal domain inhibitor JQ1, but in the opposite direction, with loss of ARID1A sensitizing breast cancer cells to bromodomain and extraterminal domain inhibition. We show that ARID1A is a repressor that binds chromatin at ER cis-regulatory elements. However, ARID1A elicits repressive activity in an enhancer-specific, but forkhead box A1-dependent and active, ER-independent manner. Deletion of ARID1A resulted in loss of histone deacetylase 1 binding, increased histone 4 lysine acetylation and subsequent BRD4-driven transcription and growth. ARID1A mutations are more frequent in treatment-resistant disease, and our findings provide mechanistic insight into this process while revealing rational treatment strategies for these patients.
Version of record
Mice, Inbred NOD
Cell Cycle Proteins
Estrogen Receptor alpha
Xenograft Model Antitumor Assays
Gene Expression Regulation, Neoplastic
Drug Resistance, Neoplasm
Hepatocyte Nuclear Factor 3-alpha
Histone Deacetylase 1
Clustered Regularly Interspaced Short Palindromic Repeats
Preclinical Modelling of Paediatric Cancer Evolution
Nature genetics, 2020, 52 (2), pp. 187 - 197